Blog
Rhode Island Legislation Recognizes Crucial Role of NPs, PAs in Providing Patient Care
By Joe Gorelick, MSN, FNP-C A 25-bill legislative package from Rhode Island legislators aimed at improving health care access and affordability in the Ocean State relies heavily on expansion of the primary care workforce, particularly NPs and PAs. RI Senate Health...
Letybo from Hugel is the Newest Botulinum Toxin Approved in US
The FDA has approved a new botulinum toxin formulation for aesthetic use in the US. Letybo from Hugel America, Inc., a division of Hugel Inc., is approved to treat moderate-to-severe glabellar (frown) lines in adults. Letybo (letibotulinumtoxinA-wlbg) is expected to...
FDA Considers Four New Indications for Bimzelx from UCB
Bimzelx® (bimekizumab-bkzx) from UCB is now under FDA review for a total of four potential new indications. Supplemental biologics license applications (sBLA) were submitted in February for three spondyloarthritides indications: psoriatic arthritis (PsA),...
NPs/PAs Provide One-Quarter of Healthcare Visits in the US
As the rate of growth of nurse practitioners (NPs) and physician assistants (PAs) in the US continues to rise rapidly, research shows that the share of healthcare visits provided by NPs and PAs has increased by 11% since 2013. According to the latest data, NPs and PAs...
Dermalorian™ Podcast: Can You Make the Diagnosis?
DERM 2023 was built around the theme of Stranger Dx™, and DERM Faculty member and DEF Advisory Council member Wendy Cantrell, DNP certainly brought a case to fit the theme. In this episode of the Dermalorian™ Podcast from the DEF, (SCROLL DOWN FOR LINKS TO EACH...
Galderma Submits BLAs for Nemolizumab for PN and AD
Galderma has submitted Biologics License Applications (BLAs) for nemolizumab for the treatment of prurigo nodularis (PN) and for moderate to severe atopic dermatitis (AD) in adolescents and adults. Nemolizumab is a first-in-class investigational monoclonal antibody...
Dermavant Submits sNDA for VTAMA for Topical Treatment of AD in Adults and Children
Dermavant Sciences has submitted a Supplemental New Drug Application (sNDA) to the U.S. FDA for Vtama® (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older. VTAMA cream, 1% is currently FDA-approved...
Study Identifies Significant Costs for Individuals with Vitiligo
By Joe Gorelick, MSN, FNP-C Patients with vitiligo incur significantly higher healthcare costs than people without the skin condition, a new study published in Journal of Investigative Dermatology shows. In addition to direct costs that may be associated with managing...
Individuality a Key Aspect of Aesthetic Treatment, Allergan Report Says
By Joe Gorelick, MSN, FNP-C Individuality drives the definition of beauty for nearly three-quarters of Americans participating in a comprehensive survey by Allergan Aesthetics, an AbbVie. "Decoding the Future of Aesthetic Individuality" also reveals that 90% of...
Novel Topical Shows Promise for Androgenetic Alopecia in Phase 2a
A new, topical small molecule drug candidate shows promise for the treatment of androgenetic alopecia, having performed well in phase 2a clinical trials. TDM-105795 from Technoderma Medicines, Inc. is potent thyromimetic that has poor systemic absorption following...
